The FDA's 503B Exclusion Proposal: What It Means for Compounded GLP-1 Patients

On April 30, 2026, the FDA proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulks list. If finalized, large-scale compounding of these three GLP-1 medications would be permanently prohibited — even in the event of a future shortage.

The public comment period closes June 29, 2026. If you're currently taking compounded GLP-1 medications, here's what this actually means for your treatment.

The Two Compounding Pathways: A Quick Refresher

If you've been reading this site, you know the compounding world has two regulatory channels. Understanding the difference is essential right now.

503A pharmacies are state-licensed pharmacies that compound patient-specific prescriptions. A doctor writes a prescription for you, and the pharmacy makes your specific medication. These pharmacies were already affected by the shortage list removals in 2025, which eliminated their ability to make "essentially a copy" of commercially available semaglutide and tirzepatide. However, many 503A pharmacies continue to compound under various legal frameworks, including personalization (altered dosing, different bases, added ingredients).

503B outsourcing facilities are FDA-registered operations that produce large batches of compounded drugs for distribution to healthcare facilities. They operate more like mini-manufacturers. The FDA's current proposal targets these facilities specifically.

What the Proposal Actually Does

The FDA found "no demonstrated clinical need" for outsourcing facilities to compound semaglutide, tirzepatide, or liraglutide from bulk drug substances. If the exclusion is finalized:

• 503B facilities cannot compound these drugs from bulk substances under any circumstance — even during a future shortage
• 503A pharmacies are not directly targeted by this specific action, though they face separate constraints from the shortage list removals
• The decision is permanent — unlike shortage designations, which can be reinstated, a bulks list exclusion forecloses the regulatory pathway entirely

Impact on Your Current Treatment

If your medication comes from a 503A pharmacy:

This specific proposal does not directly affect you. Your treatment flows through a different regulatory pathway. However, 503A compounding of GLP-1s already operates in a constrained legal environment since the shortage list removals, and continued availability depends on your pharmacy's approach to personalization and compliance.

If your medication comes from a 503B outsourcing facility:

Your supply chain is directly at risk. Many large telehealth platforms scaled their operations on 503B partnerships. If you don't know which type of pharmacy your provider uses, ask them directly: "Does my compounded medication come from a 503A pharmacy or a 503B outsourcing facility?"

The Safety Data Behind the Proposal

The FDA cited safety concerns as part of its rationale. As of early 2025, the agency had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports associated with compounded tirzepatide. Many involved dosing errors from patients self-administering incorrect doses from multi-dose vials — a problem more common with 503B facility products than patient-specific 503A preparations.

Novo Nordisk has also alleged in separate litigation that some compounded semaglutide samples contained impurity levels as high as 86% — though these claims are contested by the compounding industry.

What You Can Do Right Now

1. Ask your provider whether your medication comes from a 503A or 503B source
2. Identify backup providers that use 503A pharmacies (listed below)
3. Submit comments if you want to participate in the regulatory process — visit regulations.gov before June 29
4. Consider brand-name options — Medicare's GLP-1 Bridge starts July 1 at $50/month; Foundayo (oral) is now available

Providers Using 503A Pharmacies

Brand-Name Alternative